Type 2 Diabetes Information Center
Brain atrophy does not appear to mediate the diabetes-cognition relationship.
The American College of Cardiology published an expert consensus statement regarding decision considerations for novel cardiovascular risk reduction therapies in patients with type 2 diabetes and atherosclerotic cardiovascular disease.
Approximately 50% of deaths in people with type 2 diabetes worldwide, and approximately two-thirds of deaths in people with type 2 diabetes in the US are caused by cardiovascular disease.
The American Diabetes Association issued a position statement outlining the recognition, management, and prevention of T2D in the pediatric population.
Patients with both Parkinson disease and type 2 diabetes were more likely to have cardiovascular comorbidities than those with only Parkinson disease.
Access to ready-to-eat outlets that sell food for instant consumption is associated with greater risk for type 2 diabetes.
Intensive blood pressure control and fenofibrate use in patients with type 2 diabetes who are at high risk for cardiovascular disease may increase the risk for adverse kidney events.
Gastric banding and metformin resulted in similar improvements in insulin sensitivity in moderately obese adults with impaired glucose tolerance or mild T2D over a 2-year period.
Researchers found that higher levels of fatty acid biomarkers 15:0, 17:0, and trans-16:1n7 were inversely associated with risk for T2D.
Researchers analyzed how improvements in metabolic syndrome may impact the risk of developing type 2 diabetes and cardiovascular disease in patients with prediabetes.